Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 7, 2012, Pages 1746-1748

  Mikulska, M ^a   Furfaro, E ^a   Del Bono, V ^a   Raiola, A M ^a   Ratto, S ^a   Bacigalupo, A ^a   Viscoli, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

ELISA; False positivity; Fungal infection; Platelia Aspergillus

Indexed keywords

GALACTOMANNAN; PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; BLOOD SAMPLING; CARBOHYDRATE ANALYSIS; FALSE POSITIVE RESULT; GALACTOMANNAN ASSAY; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY;

ANTI-BACTERIAL AGENTS; ASPERGILLOSIS; FALSE POSITIVE REACTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MANNANS; PENICILLANIC ACID; PIPERACILLIN;

EID: 84862677950     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks111     Document Type: Article

References (11)

1. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
2. Adam O, Auperin A, Wilquin F et al. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917-20.
3. Machetti M, Furfaro E, Viscoli C. Galactomannan in piperacillin-tazobactam: how much and to what extent? Antimicrob Agents Chemother 2005; 49: 3984-5.
4. Machetti M, Majabo MJ, Furfaro E et al. Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis. J Antimicrob Chemother 2006; 58: 806-10.
5. Viscoli C, Machetti M, Cappellano P et al. False-positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-6.
6. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 2366-7.
7. Walsh TJ, Shoham S, Petraitiene R et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42: 4744-8.
8. Singh N, Obman A, Husain S et al. Reactivity of Platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother 2004; 48: 1989-92.
9. Mikulska M, Raiola AM, Bruno B et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44: 361-70.
10. Stynen D, Goris A, Sarfati J et al. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33: 497-500.
11. Marr KA, Laverdiere M, Gugel A et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-9.